What is new about ovarian malignancies?

Grabska, Kinga; Pilarska, Izabela; Fudalej, Marta; Deptała, Andrzej; Badowska-Kozakiewicz, Anna M.

doi:10.5114/wo.2021.112037

Cited by 3 publications

(2 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This low relative survival is mainly attributed to inadequate screening programs and late patient presentation at diagnosis [3]. Ovarian cancers can be divided into two main types: epithelial and non-epithelial, with epithelial being more dominant [4]. Under these two classifications are many types of histological subtypes that differ in various aspects, including pathology and clinical features [5].…”

Section: Introductionmentioning

confidence: 99%

Cytochrome 4Z1 Expression Connotes Unfavorable Prognosis in Ovarian Cancers

et al. 2022

View full text Add to dashboard Cite

Background and Objective: Ovarian cancer is a leading cause of death in females. Since its treatment is challenging and causes severe side effects, novel therapies are urgently needed. One of the potential enzymes implicated in the progression of cancers is Cytochrome 4Z1 (CYP4Z1). Its expression in ovarian cancer remains unknown. Therefore, the current study aims to assess CYP4Z1 expression in different subtypes of ovarian cancers. Materials and Methods: Immunohistochemistry was used to characterize CYP4Z1 expression in 192 cases of ovarian cancers along with eight normal ovarian tissues. The enzyme’s association with various clinicopathological characteristics and survival was determined. Results: CYP4Z1 was strongly expressed in 79% of ovarian cancers, compared to negative expression in normal ovarian samples. Importantly, significantly high CYP4Z1 expres-sion was determined in patients with advanced-stage cancer and a high depth of invasion (p < 0.05). Surprisingly, CYP4Z1 expression was significantly associated with a low patient survival rate. Univariate analysis revealed that patient survival was strongly associated with CYP4Z1 expression, tumor stage, depth of invasion, and lymph node metastasis (p < 0.05). Multivariate analysis showed that only CYP4Z1 expression was significantly associated with patient survival (p < 0.05). Conclusions: CYP4Z1 expression is correlated with shorter patient survival and has been identified as an independent indicator of a poor prognosis for ovarian cancer patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Cytochrome 4Z1 Expression Connotes Unfavorable Prognosis in Ovarian Cancers

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Ovarian cancer has a poor prognosis and is one of the major causes of death in patients with gynecologic malignancies due to its late detection and the high level of angiogenesis. 1,2) The introduction of antiangiogenic drugs such as bevacizumab, and poly(ADP-ribose) polymerases (PARP)-inhibitors such as olaparib or niraparib, has highlighted the potential of novel pharmacological treatments for ovarian cancers. 2) However, standard treatments have remained largely unaltered over the past few decades, and platinum-based chemotherapy combined with paclitaxel is still the first-line therapy.…”

Section: Introductionmentioning

confidence: 99%

The Impact of Eribulin on Stathmin Dynamics and Paclitaxel Sensitivity in Ovarian Cancer Cells

Azumi

Yoshie

Takano

et al. 2022

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Eribulin, an inhibitor of microtubule dynamics, is used for treating breast cancers and sarcomas. The microtubule-destabilizing protein stathmin may modulate the antiproliferative activity of eribulin on breast cancer cells and leiomyosarcoma cells. The antitumor activity of eribulin in ovarian cancers has not been fully explored, so the present study aimed to determine the antitumor efficacy of eribulin and the involvement of stathmin in ovarian cancers. In a xenograft model of ovarian cancer, eribulin treatment reduced the tumor weight, which was accompanied by an increased level of phosphorylated stathmin. Eribulin stimulated the phosphorylation of stathmin in cultured cancer cell lines. The eribulin-induced phosphorylation of stathmin was inhibited by treatment with FTY720, an activator of protein phosphatase 2A (PP2A), and eribulin downregulated the expression of PP2A subunits. Furthermore, stathmin knockdown abrogated the inhibitory effects of eribulin on cell viability. Eribulin enhanced the antiproliferative effects of paclitaxel and concomitantly decreased stathmin expression. These results suggest that eribulin-induced phosphorylation of stathmin, mediated in part by PP2A downregulation, reduces stathmin activity and enhances the antiproliferative effects of paclitaxel in ovarian cancer. Collectively, the results of this study indicate that eribulin may suppress the proliferation of ovarian cancer cells partly by regulating the activity of stathmin.

show abstract

Patient‐derived ovarian cancer organoid carries immune microenvironment and blood vessel keeping high response to cisplatin

Zhao,

Wang,

Deng

et al. 2024

MedComm

View full text Add to dashboard Cite

Ovarian cancer is high recurrence and mortality malignant tumor. The most common ovarian cancer was High‐Grade Serous Ovarian Cancer. However, High‐Grade Serous Ovarian Cancer organoid is rare, which organoid with patient immune microenvironment and blood vessels even absence. Here, we report a novel High‐Grade Serous Ovarian Cancer organoid system derived from patient ovarian cancer samples. These organoids recapitulate High‐Grade Serous Ovarian Cancer organoids' histological and molecular heterogeneity while preserving the critical immune microenvironment and blood vessels, as evidenced by the presence of CD34+ endothelial cells. Whole exome sequencing identifies key mutations (CSMD3, TP53, GABRA6). Organoids show promise in testing cisplatin sensitivity for patients resistant to carboplatin and paclitaxel, with notable responses in cancer proteoglycans and p53 (TP53) signaling, like ACTG/ACTB1/AKT2 genes and BBC3/MDM2/PERP. Integration of immune microenvironment and blood vessels enhances potential for novel therapies like immunotherapies and angiogenesis inhibitors. Our work may provide a new detection system and theoretical basis for ovarian cancer research and individual therapy.

show abstract

What is new about ovarian malignancies?

Cited by 3 publications

References 76 publications

Cytochrome 4Z1 Expression Connotes Unfavorable Prognosis in Ovarian Cancers

Cytochrome 4Z1 Expression Connotes Unfavorable Prognosis in Ovarian Cancers

The Impact of Eribulin on Stathmin Dynamics and Paclitaxel Sensitivity in Ovarian Cancer Cells

Patient‐derived ovarian cancer organoid carries immune microenvironment and blood vessel keeping high response to cisplatin

Contact Info

Product

Resources

About